Innate Pharma S.A. (IPHA)Healthcare | Biotechnology | Marseille, France | NasdaqGS
1.66 USD
+0.04
(2.469%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.82 +0.16 (9.639%) ⇧ (April 17, 2026, 7:52 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:41 p.m. EDT
Short-term volatility with a statistically significant downside forecast (-4.18% predicted move over 45 days) creates a sell bias despite catalyst-driven upside variance; long-term outlook remains weak due to contractive fundamentals and lack of earnings, while dividend yield is nonexistent. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.095960 |
| AutoARIMA | 0.140922 |
| AutoETS | 0.140999 |
| MSTL | 0.143526 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 74.20 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.093 |
| Excess Kurtosis | -1.06 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.101 |
| Market Cap | 155,756,448 |
| Forward P/E | -2.65 |
| Beta | 0.75 |
| Website | https://www.innate-pharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.1398964 |
| Address1 | 117, Avenue de Luminy |
| Address2 | BP 30191 |
| All Time High | 11.95 |
| All Time Low | 1.17 |
| Ask | 1.68 |
| Ask Size | 1 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 38,500 |
| Average Daily Volume3 Month | 23,324 |
| Average Volume | 23,324 |
| Average Volume10Days | 38,500 |
| Beta | 0.745 |
| Bid | 1.86 |
| Bid Size | 1 |
| Book Value | -0.2737159 |
| City | Marseille |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.66 |
| Current Ratio | 1.275 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.7079 |
| Day Low | 1.6006 |
| Display Name | Innate Pharma |
| Earnings Call Timestamp End | 1,774,530,000 |
| Earnings Call Timestamp Start | 1,774,530,000 |
| Earnings Timestamp | 1,778,675,400 |
| Earnings Timestamp End | 1,778,675,400 |
| Earnings Timestamp Start | 1,778,675,400 |
| Ebitda | -53,309,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.7 |
| Enterprise To Revenue | 15.986 |
| Enterprise Value | 143,954,464 |
| Eps Current Year | -0.543 |
| Eps Forward | -0.627 |
| Eps Trailing Twelve Months | -0.65 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 33 4 30 30 30 00 |
| Fifty Day Average | 1.5292 |
| Fifty Day Average Change | 0.13080001 |
| Fifty Day Average Change Percent | 0.08553493 |
| Fifty Two Week Change Percent | -13.989639 |
| Fifty Two Week High | 2.63 |
| Fifty Two Week High Change | -0.97000015 |
| Fifty Two Week High Change Percent | -0.36882132 |
| Fifty Two Week Low | 1.17 |
| Fifty Two Week Low Change | 0.49 |
| Fifty Two Week Low Change Percent | 0.41880345 |
| Fifty Two Week Range | 1.17 - 2.63 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,571,319,000,000 |
| Float Shares | 65,897,822 |
| Forward Eps | -0.627 |
| Forward P E | -2.647528 |
| Free Cashflow | -34,073,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 163 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -34,615,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0167 |
| Held Percent Institutions | 0.00294 |
| Implied Shares Outstanding | 93,829,188 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France. |
| Long Name | Innate Pharma S.A. |
| Market | us_market |
| Market Cap | 155,756,448 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_426137 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -49,177,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 152,090,435 |
| Number Of Analyst Opinions | 4 |
| Open | 1.6101 |
| Operating Cashflow | -52,755,000 |
| Operating Margins | -6.89554 |
| Payout Ratio | 0.0 |
| Phone | 33 4 30 30 30 30 |
| Post Market Change | 0.16000009 |
| Post Market Change Percent | 9.638559 |
| Post Market Price | 1.82 |
| Post Market Time | 1,776,469,945 |
| Previous Close | 1.62 |
| Price Eps Current Year | -3.0570903 |
| Price Hint | 4 |
| Price To Book | -6.064682 |
| Price To Sales Trailing12 Months | 17.296663 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.144 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 0.04 |
| Regular Market Change Percent | 2.46913 |
| Regular Market Day High | 1.7079 |
| Regular Market Day Low | 1.6006 |
| Regular Market Day Range | 1.6006 - 1.7079 |
| Regular Market Open | 1.6101 |
| Regular Market Previous Close | 1.62 |
| Regular Market Price | 1.66 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 50,318 |
| Return On Assets | -0.38849 |
| Revenue Growth | -0.467 |
| Revenue Per Share | 0.101 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 93,829,188 |
| Shares Percent Shares Out | 0.0008 |
| Shares Short | 71,264 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 99,192 |
| Short Name | Innate Pharma S.A. |
| Short Percent Of Float | 0.0008 |
| Short Ratio | 3.29 |
| Source Interval | 15 |
| Symbol | IPHA |
| Target High Price | 8.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 6.0 |
| Target Median Price | 6.5 |
| Total Cash | 34,310,000 |
| Total Cash Per Share | 0.366 |
| Total Debt | 22,573,000 |
| Total Revenue | 9,005,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.65 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.837385 |
| Two Hundred Day Average Change | -0.17738509 |
| Two Hundred Day Average Change Percent | -0.09654214 |
| Type Disp | Equity |
| Volume | 50,318 |
| Website | https://www.innate-pharma.com |
| Zip | 13,009 |